Can This Struggling Drugmaker Overcome Generic Statins?

The Motley Fool's health-care show, Market Checkup, focuses this week on cholesterol, one of America's most notable health-care concerns.

According to the CDC, approximately 71 million Americans have high cholesterol, and less than 50% actually get treated. High levels of LDL cholesterol, commonly known as "bad" cholesterol, can lead to dangerous health problems, including heart disease and high blood pressure. In the following segment, health-care analysts David Williamson and Max Macaluso discuss how sales of AstraZeneca's cholesterol-lowering statin Crestor are threatened by competing generic drugs.

Many investors are attracted to the hefty dividends of pharma companies such as AstraZeneca, but savvy investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The article Can This Struggling Drugmaker Overcome Generic Statins? originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.